Close Menu

NEW YORK (360Dx) – Qurin Diagnostics, a Dutch molecular diagnostics company, is moving ahead with plans to develop and launch photonics-based biochips for early-stage detection of cancer.

Last month, the Enschede-based firm together with Lionix International, a manufacturer of photonic integrated circuit modules, acquired a majority stake in Surfix, a provider of custom-made nanocoatings. Lionix and Surfix are also based in the Netherlands.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Sponsored by

This webinar will discuss how the Molecular Pathology Laboratory at the University of Oklahoma (OUMP) is using a new quality improvement model to support molecular testing of oncology patients. 


This webinar will discuss the evolution of fetal aneuploidy screening and the most recent evidence around the implementation of prenatal cell-free DNA testing in clinical practice.